This conference provides a space for those directly involved in cementing the details of partnerships with big pharma, biotechs, academia and non-profit organisations to share their case studies and gain insight into best practice. If you are looking for potential partnerships and collaborations, makes sure you participate in this conference to meet new vaccine biotechs showcasing their technology and pipeline.
• National and International Government
• Non-Profit Organizations
• Academics and Research Institutions
• Venture capitalists
• CEO / CSO / COO
• Head of Corporate Development
• Head of Licensing/Out-Licensing
• Head of Pipeline Management
• Head of Outsourcing
• Head of Strategy
• Head of Alliancing/alliance management
• Head of Legal/Contracts
• Partner strategy and implementation lead
• External R&D
Who Should Sponsor?
• Platform Technology Providers
• Big Pharma
• Consultants with expertise in vaccine development and execution
• Consultants on Legal affairs
• Consultants on Regulatory Affairs
Vaccine Partnerships Conference, Tuesday 16 April 2019
Chair’s opening remarks
Can vaccines lessen the burden of antibiotic resistance?
-Who is CARB-X-What vaccines programs they are supporting -What they are looking for in a partner, public-private partnerships
FireChat 1 – FireChat 1 – Bacterial Vaccine
FireChat 2 – Reducing Bacterial Adherence May Lessen Morbidity and Mortality caused by Urinary Tract Infections
FireChat 3 – A combination, live attenuated, oral vaccine against Shigella and ETEC infections
FireChat 4 – DNA vaccine
FireChat 5 – Developing infectious disease vaccine using mRNA technologies for pharmacologically optimized protein coding RNA
FireChat 6 – Developing novel cancer immunotherapies based on optimized, antigen-encoding and complexed mRNA molecules
FireChat 7 – A Single Intranasal Immunization with M2SR (M2 deletion, single replication) Vaccine Protects Against a Substantially Drifted H3N2 Influenza Virus in Human Challenge Study
Strategies for Effective Partnerships with the US Government, NGOs, International Collaborators and Beyond.
-How both companies identified the initial match?-How the responsibilities of each party were determined-Lessons learned so far and what both parties hope to achieve
-Objectives of a public-private partnership -How were the partners resourced-What was the outcome of the collaboration
last published: 25/Mar/19 10:45
Vaccine Partnerships Conference, Wednesday 17 April 2019
NIH – Emerging Diseases, Vaccination and Immunization Strategy
UNICEF – An update on vaccine procurement and global immunization strategy
EDCTP – Public-Private partnership between Europe and sub-Saharan Africa to accelerate the development of vaccines
NVPO – Priorities and how to improve vaccination system in the US, Adult Immunization, Vaccine Safety
Melinda Wharton, Director, Imm Svcs Division, CDC
NVAC – National Vaccine Plan Strategy, Topics affecting Vaccine Enterprise
Representatives from: Europe, Africa, Mexico, Saudi, South America- Challenges and disease targets of each market- Funding opportunities - Perspective partnerships
Chair's opening remarks
- What have we learnt from previous vaccines failures to drive new vaccines forward?
- Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
- Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
A framework for a comprehensive maternal immunization platform
- Evidence for current immunization recommendations
- Maternal vaccines in development
- The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
- An industry pipeline dissection
- Which type of companies are engaged in these programs?
- Where will the innovation come from?
- Incentives, insights and potential solutions
last published: 25/Mar/19 10:45